-+ 0.00%
-+ 0.00%
-+ 0.00%

Guggenheim Reiterates Buy on AbbVie, Maintains $288 Price Target

Benzinga·10/09/2026 13:23:08
Guggenheim analyst Vamil Divan reiterates AbbVie (NYSE:ABBV) with a Buy and maintains $288 price target.